Pazocam 200mg Tablet contains Pazopanib Hydrochloride, equivalent to 200mg of Pazopanib, a potent oral multi-kinase inhibitor. Classified under protein kinase inhibitors, it is primarily used in the treatment of certain advanced cancers. By selectively targeting tumour growth pathways, Pazocam helps in slowing down or halting the progression of malignancies. Its availability in oral tablet form ensures ease of administration, supporting outpatient cancer care

Mechanism of Action

Pazopanib is a tyrosine kinase inhibitor (TKI).

• It specifically targets and blocks multiple receptor tyrosine kinases involved in tumour growth and angiogenesis (formation of new blood vessels that supply the tumour).

• These include vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), and c-Kit.

• By inhibiting these kinases, Pazopanib reduces tumour vascularisation, depriving cancer cells of oxygen and nutrients needed to grow and spread.

  Uses / Indications

  Pazocam is indicated for the treatment of:

  • Advanced Renal Cell Carcinoma (RCC): To help control cancer that starts in the kidney.

  • Advanced Soft Tissue Sarcoma (STS): In patients who have received prior chemotherapy.

  It is prescribed under oncologist supervision, often after other treatments have been tried, to help extend progression-free survival.

  Adverse Effects

  Like many cancer therapies, Pazocam may cause side effects. Not every patient experiences all of them, but awareness helps in prompt management.
  Common adverse effects include:

  • Gastrointestinal issues: nausea, vomiting, diarrhoea, loss of appetite.

  • Liver enzyme elevations: requiring regular liver function monitoring.

  • Hypertension (high blood pressure): which may necessitate additional medicines.

  • Hair colour changes or thinning.

  • Fatigue, weakness or general malaise.